The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Phase III EMERALD-1: bevacizumab and durvalumab with TACE improves PFS in unresectable HCC
Stephen Lam Chan, MD, FRCP, Chinese University of Hong Kong, Hong Kong, China, discusses the Phase III EMERALD-1 study (NCT03778957) as a potentially groundbreaking investigation for patients with unresectable hepatocellular carcinoma. The study reveals that combining bevacizumab and durvalumab with transarterial chemoembolization (TACE) significantly improves progression-free survival. Subgroup analyses indicate that benefits extend across various tumor burdens, hepatic functions, etiologies, and geographical regions. This combination therapy could become a new treatment option for patients undergoing TACE, with the added systemic treatments enhancing progression-free survival. Additionally, the safety analysis confirms that this regimen is well-tolerated without significant toxicity. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – AstraZeneca; Eisai; Ipsen; Roche
Consulting or Advisory Role – AstraZeneca; BMS; Eisai; MSD Oncology; Roche
Research Funding – Eisai; Ipsen
